secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-08-28T20:31:33+00:00
Accession:  0001140361-26-034854
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Roivant's LISRAYA (brepocitinib) for dermatomyositis at $35K WAC
-----------------------------------------------------------------------------

- FDA granted approval of LISRAYA (brepocitinib) for adult dermatomyositis on Aug 28, 2026.
- Wholesale acquisition cost set at $35,000 per 30-count bottle of 30 mg tablets.
- No additional financial or commercial launch details disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/0001140361-26-034854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-034854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer